RxSight (RXST) Projected to Announce Earnings on Wednesday

RxSight (NASDAQ:RXST) will likely be posting its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect RxSight to post earnings of ($0.21) per share and revenue of $32.47 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

RxSight Stock Up 0.6%

RXST stock traded up $0.04 during midday trading on Wednesday, hitting $6.08. 79,824 shares of the company traded hands, compared to its average volume of 979,143. RxSight has a twelve month low of $4.48 and a twelve month high of $13.22. The stock has a market capitalization of $251.92 million, a price-to-earnings ratio of -5.38 and a beta of 1.15. The business has a 50 day simple moving average of $5.27 and a 200-day simple moving average of $6.82.

Institutional Trading of RxSight

Several institutional investors have recently made changes to their positions in RXST. Virtu Financial LLC acquired a new position in RxSight in the fourth quarter worth about $156,000. Invesco Ltd. lifted its stake in RxSight by 6.6% during the fourth quarter. Invesco Ltd. now owns 20,114 shares of the company’s stock worth $210,000 after purchasing an additional 1,249 shares during the period. Corient Private Wealth LLC boosted its holdings in RxSight by 17.9% during the fourth quarter. Corient Private Wealth LLC now owns 35,570 shares of the company’s stock valued at $371,000 after purchasing an additional 5,408 shares in the last quarter. Tudor Investment Corp ET AL acquired a new stake in RxSight during the fourth quarter valued at approximately $201,000. Finally, Boothbay Fund Management LLC bought a new stake in shares of RxSight in the 4th quarter valued at approximately $123,000. 78.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

RXST has been the subject of several recent analyst reports. Wall Street Zen raised shares of RxSight from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. UBS Group reissued a “neutral” rating and set a $5.50 target price (down from $9.00) on shares of RxSight in a research report on Tuesday. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of RxSight in a research report on Tuesday, July 7th. Weiss Ratings cut shares of RxSight from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Finally, Wells Fargo & Company lowered their price target on RxSight from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Thursday, May 7th. Two analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, RxSight presently has a consensus rating of “Reduce” and a consensus price target of $8.50.

About RxSight

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non?invasive post?operative adjustments. Using ultraviolet light, surgeons can fine?tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.